A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Latest Information Update: 21 Oct 2022
At a glance
- Drugs Abiraterone (Primary) ; Cirtuvivint (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Biosplice Therapeutics
- 18 Oct 2022 Planned primary completion date changed from 1 Jul 2026 to 1 Jul 2024.
- 18 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 29 Sep 2022 According to a Biosplice Therapeutics media release, preliminary data from this trial were presented at the 2022 European Society for Clinical Oncology (ESMO) meeting.